BIOX: Stable 4Q26 revenues and cost cuts improved EBITDA, but FY26 saw lower sales and ongoing legal risks
Revenues were stable in 4Q26 but declined 18% for FY26, mainly due to Seeds business reconfiguration and lower HB4 activities. Cost reductions improved Adjusted EBITDA and narrowed net losses, while ongoing legal disputes and capital structure challenges remain key risks.Original document: Bioceres…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.